Navigation Links
Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
Date:10/8/2015

ATLANTA, Oct. 8, 2015 /PRNewswire/ -- Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for its flagship compound, acebilustat, in patients with cystic fibrosis (CF). The study will be conducted at approximately 60 sites in the United States and European Union, with the EU sites anticipated to begin enrollment early 2016. This landmark clinical trial testing once-daily oral acebilustat treatment over 48 weeks could be the first to establish proof-of-concept for an anti-inflammatory treatment specifically designed to prevent long-term loss of lung function in CF patients. The study will test once daily oral doses of 50 mg and 100 mg acebilustat against placebo on top of background therapy in adult CF patients.

Acebilustat is a first-in-class neutrophil modulator that controls a key inflammatory signal overexpressed in CF and other orphan inflammatory diseases. Acebilustat has been granted orphan drug status for the treatment of CF in the US and the EU.  Results from initial clinical studies in CF patients demonstrated acebilustat's ability to moderate the over-activated inflammatory response in CF, decreasing neutrophils in the lung by 65% and decreasing damaging neutrophil elastase in just two weeks of treatment. Acebilustat did this without jeopardizing the patient's immune response to infection. Importantly, acebilustat treatment is applicable to all CF patients irrespective of their gene mutation and can be used on top of background therapy, including Kalydeco and Orkambi.

The Phase 2 CF trial was designed in conjunction with and supported by a grant from Cystic Fibrosis Foundation Therapies, Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. It will include approximately 30 sites in the US under the oversight of Principal Investigator Dr. Stephen Rowe MD MSPH, Professor at the University of Alabama Birmingham School of Medicine, Director of the Cystic Fibrosis Transition Clinic, and Director of the CFFT Development Network Center for CFTR Detection. Said Dr. Rowe, "CF patients are in desperate need of efficacious and safe anti-inflammatory therapies to control progressive lung disease.  Evaluation of the long term effects of acebilustat is a very important step in that direction, given the favorable Phase 1b results in CF patients."

For more information, please visit http://clinicaltrials.gov/show/NCT02443688.

Logo - http://photos.prnewswire.com/prnh/20150605/221207LOGO


'/>"/>
SOURCE Celtaxsys, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF)
2. Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris - Recruitment of Patients to Commence Immediately
3. Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer
4. Greg Duncan Appointed President and Chief Executive Officer of Celtaxsys, Inc.
5. Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430
6. Celtaxsys Restructures, Enhances Operational Focus
7. Construction Begins at Genovate Biotechnologys Insulin Ecological Industrial Park in Chinas Changzhou National Hi-tech District
8. NOWDiagnostics Inc. Begins Manufacturing New Point-of-Care Tests Capable of Providing Results in Just Minutes with the Same Reliability as Lab-Based Tests
9. Worlds Most Technologically Advanced Cannabis Cultivation Facility And Laboratory Begins Operating In Delavan, Illinois
10. GSK begins shipping 2015-16 US flu vaccines with focus on customer needs, volume, and speed
11. Aethlon Medical Begins Trading on the Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2019)... ... 2019 , ... A leading global health expert urged new Western University of ... health care successes and builds on them to make better lives for all the ... health at the University of Washington and Institute Director of the Institute for Health ...
(Date:5/22/2019)... ... 2019 , ... CBDNhance, a new player in the rapidly-growing ... designed to increase the benefits of CBD, especially for people seeking pain relief ... other natural ingredients that have been shown to help with CBD absorption and ...
(Date:5/22/2019)... ... May 22, 2019 , ... Americans can save more money on ... by PharmacyChecker.com which compared prices on the top-selling generic drugs. Eighty-eight percent of the ... medications; however, are far lower at Canadian and other international online pharmacies ...
Breaking Medicine Technology:
(Date:5/23/2019)... ... May 23, 2019 , ... In the U.S. in ... 1,092 embryo transfer procedures, the last step in the in vitro fertilization (IVF) process. ... five years earlier.[1] Dr. Mark P. Trolice, Director of Fertility CARE: The IVF ...
(Date:5/23/2019)... ... , ... Dr. Earl Stephenson, board-certified Face Expert representing the ... Network, well known for their exclusivity, and luxurious lifestyle, is privileged to present ... Haute Living partnership. , Haute Beauty offers a prominent collective of leading doctors ...
(Date:5/23/2019)... ... ... years after losing her daughter to injuries sustained during an stone-throwing attack in the West ... Sheba Medical Center, Tel HaShomer . The baby was born on the same birth date ... , “Just as we live with our loss 24/7, we are choosing life and continue ...
(Date:5/23/2019)... ... 2019 , ... Summit BHC (Summit), a leading provider of ... center, Bel Aire Recovery Center. Located in the suburbs of Wichita, Kansas, the ... is located in the natural landscape of the beautiful Kansas prairie. , Residential ...
(Date:5/23/2019)... ... 2019 , ... Join Dr. Ashok Srivastava, CEO & CMO at ClinFomatrix and ... at OmniComm Systems, Inc. , in a live webinar on Tuesday, ... benefits of visual patient profiles. Together, the two speakers bring years of experience in ...
Breaking Medicine News(10 mins):